# US 9,872,889 B2 · Activators of CXCR3 for the treatment of angiopathies of the eye

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,889 B2
- Document ID: US9872889B2
- Status: Granted
- Kind: B2
- Application number: 15/245,502
- Filed: 2016-08-24
- Published: 2016-12-15
- Granted: 2018-01-23
- Earliest claimed: 2011-08-26
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Alan H. Wells; Cecelia C. Yates-Binder; Joel S. Schuman
- Web page: https://patentgrep.com/patent/US9872889B2

## CPC

- A61K 38/195: {Chemokines, e.g. RANTES}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 38/217: {IFN-gamma}
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-γ-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.

## Claims

### Claim 1

A method of treating an angiogenic disorder of the eye, or treating aberrant angiogenesis of the eye in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an activator of C-X-C chemokine receptor 3 (CXCR3), wherein the CXCR3 activator is a biologically active interferon-γ-inducible 10 kDa protein (IP-10) peptide fragment consisting of SEQ ID NO: 6, thereby treating the angiogenic disorder, or treating the aberrant angiogenesis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the angiogenic disorder of the eye is an intraocular angiogenic disorder.

### Claim 3 (depends on 2)

The method of claim 2, wherein the intraocular angiogenic disorder is restenosis following glaucoma treatment, wet macular degeneration, diabetic retinopathy, retinopathy of prematurity or neovascular glaucoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the CXCR3 activator is conjugated to polyethylene glycol (PEG) or dextran.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CXCR3 activator is administered topically, by injection or by medical implant.

### Claim 6 (depends on 5)

The method of claim 5, wherein the CXCR3 activator is administered by injection into the vitreous humor or the aqueous humor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CXCR3 activator is present in a pharmaceutically acceptable carrier acceptable for administration to the eye.